An Open-Label, Phase 1, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2017
At a glance
- Drugs M 9831 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 06 Dec 2017 Status changed from active, no longer recruiting to completed.
- 14 Nov 2017 Planned End Date changed from 1 Dec 2018 to 17 Nov 2017.
- 14 Nov 2017 Planned primary completion date changed from 1 Sep 2018 to 17 Nov 2017.